4
Participants
Start Date
October 1, 2020
Primary Completion Date
April 30, 2032
Study Completion Date
April 30, 2032
SPK-3006
adeno-associated viral (AAV) vector
Nice University Hospital, Nice
Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino - Neurology, Osp. Molinette, Torino
University of Pittsburgh Medical Center, Pittsburgh
University of Pennsylvania, Philadelphia
Lysosomal and Rare Disorders Research & Treatment Center, Fairfax
Emory University School of Medicine, Atlanta
Centre Hospitalier Universitaire d'Angers, Angers
University of Minnesota, Minneapolis
UO Neurologia Azienda Ospedaliera Universitaria Pisana, Pisa
Centre Hospitalier Régional Universitaire de Lille, Lille
University of Kansas Medical Center Research Institute, Kansas City
Malattie Metaboliche Universita Degli Studi Di Napoli Federico II, Naples
University of Utah, Salt Lake City
Barrow Neurological Institute, Phoenix
CHU Paris IdF Ouest - Hôpital Raymond Poincaré, Garches
University of California Irvine Health, Orange
Oregon Health & Science University, Portland
Universita Degli Studi Di Messina - Dipartimento di Medicina Clinica e Sperimentale, Messina
Vancouver General Hospital, Vancouver
The Ottawa Hospital, Ottawa
Montreal Neurological Hospital, Montreal
Rigshospitalet, Copenhagen
Assistance Publique Hôpitaux de Marseille, Marseille
Friedrich-Baur-Institut Neurologische Klinik Ludwig-Maximilians-Universität München, München
Universita Degli Studi Di Milano, Laboratorio di Biochimica e Genetica della Malattie Neuromuscolari, Milan
Erasmus Medical Center, Rotterdam
New Queen Elizabeth Hospital Birmingham, Birmingham
The Royal Free London NHS Foundation Trust, London
Salford Royal MHS Foundation Trust, Salford
Spark Therapeutics, Inc.
INDUSTRY